AZD7442 - a new monoclonal antibody administer... - CLL Support
AZD7442 - a new monoclonal antibody administered by intramuscular injection is a potential game changer for CLL patients at risk of COVID-19
You need to be a member of this community to see this post.
Read more about...
6 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
STORM CHASER MISSES THE TARGET
SARS-CoV-2 virus. https://www.clinicaltrialsarena.com/news/astrazeneca-covid-drug-trial-data/ The...
Calling UK CLLers - Is government about to abandon support for protective monoclonal antibodies?
Regeneron and Astrazeneca...
Which monoclonal antibody would work with omicron covid 19?
Which monoclonal antibody would work with omicron covid 19?
Reposted from CLLSLL@groups.io :...
UK first to trial AstraZeneca 'antibody cocktail' aimed at non-vaccine patients
the COVID vaccines may not be effective https://www.lbc.co.uk/news/uk-first-to-trial-astrazeneca-ant
COVID risk to CLL patients with the reopening of schools
that COVID presents.
We were fortunate that a politician has taken up our cause and I will post...
COVID-19 Particularly Risky for CLL Patients
UK Zoom meeting - COVID-19 and shielding update for UK CLL Patients
COVID-19 among fit patients with CLL treated with venetoclax-based combinations
Combining the Influenza and COVID-19 vaccines.
Good news on vaccine efficacy for the 80%
